Cardiothoracic & vascular anesthesia
Hydroxocobalamin for vasoplegia in cardiac surgery: a retrospective cohort analysis
Authors' conclusion
Hydroxocobalamin administration was associated with reduced vasopressor requirement over 24 h, but not thereafter.
Study context
- Population
- Patients who developed vasoplegia after CPB, 2018–2024229 matched pairs
- Participants
- 229 vs 229
- Exposure
- Hydroxocobalamin vs no hydroxocobalamin
- Hydroxocobalaminn = 229
- Referencen = 229reference
- Outcome
- Vasopressor requirement, as norepinephrine equivalents (NEE)
- Follow-up
- 1, 4, 24, and 48 h after treatment
Methodological detailssingle-centre, propensity-matched
- Single-centre
- Propensity-matched
Main finding
As reported in the abstract
Median NEE infusion rate
Hydroxocobalamin vs ReferenceDifference, μg kg-1 min-1 (95% CI)P value
At 1 h
−0.04(−0.07 to −0.02)
P = 0.008At 4 h
−0.05(−0.07 to −0.02)
P < 0.001At 24 h
−0.04(−0.06 to −0.02)
P = 0.004At 48 h
−0.02(−0.05 to 0.0)
P = 0.220- Norepinephrine equivalents (NEE) reduced over the initial 24 h vs reference
- 14%
Observational data: associations, not effects.
Secondary outcomes
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Composite in-hospital complications (stroke, sternal wound infection, mesenteric ischaemia, renal failure, death)Similar in each group | 1.06 (0.74–1.54) | P = 0.745 | |
| 0.512Odds ratio (log scale) |
Original publication
Hydroxocobalamin for vasoplegia in cardiac surgery: a retrospective cohort analysis. Br J Anaesth. Published 8 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →